Table 8.6i
Immunosuppression Use for Antirejection Treatment from Transplant to One Year Following Transplantation, 1995 to 2004
Recipients with Kidney-Pancreas Transplants

	Year of Transplant									
	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Transplants	919	861	853	972	942	915	891	905	871	881
Tx with Antirejection Treatments	622	565	317	286	261	232	194	192	154	126
Antibodies										
Any in Category	47.6%	31.3%	46.7%	44.4%	42.1%	41.4%	32.0%	50.5%	57.8%	62.7%
ALG	8.4%	0.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	6.9%	8.8%	18.3%	10.1%	6.5%	3.9%	0.5%	2.6%	1.9%	3.2%
OKT3	41.5%	24.8%	34.7%	35.7%	24.5%	22.8%	12.4%	10.4%	9.7%	11.9%
Thymoglobulin	0.0%	0.0%	0.3%	3.1%	16.1%	15.1%	20.6%	33.9%	39.6%	43.7%
Zenapax	0.0%	0.0%	0.3%	1.7%	1.5%	1.7%	1.0%	4.7%	11.7%	7.1%
Simulect	0.0%	0.0%	0.0%	0.0%	0.4%	2.2%	0.5%	1.0%	1.3%	1.6%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.5%	3.9%	2.4%
Corticosteroids										
Any in Category	66.2%	55.2%	69.1%	77.6%	80.5%	82.8%	86.6%	76.6%	68.8%	69.0%
Steroids	66.2%	55.2%	69.1%	77.6%	80.5%	82.8%	86.6%	76.6%	68.8%	69.0%
Antimetabolites										
Any in Category	0.2%	0.2%	0.0%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Cytoxan	0.2%	0.2%	0.0%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Methotrexate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.